Thu, Aug 28, 2014, 7:50 AM EDT - U.S. Markets open in 1 hr 40 mins


% | $
Quotes you view appear here for quick access.

Zillow, Inc. Message Board

franchise_approval 3 posts  |  Last Activity: Apr 25, 2014 8:28 AM Member since: Nov 19, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • R&D already reduced this quarter, further reduced by year-end. Existing sales on current products justify current price. Calcitrol retest highs, Triferric = ICPT

  • franchise_approval franchise_approval Mar 8, 2014 8:20 AM Flag

    You are dead on EAi I!!!!! This is exactly the reason why Amgen is shutting down their Epogen manufacturing facilities. An article published January, 2014 says Amgen is cutting 200 jobs at Colorado's manufacturing facility as they realize Triferic will ultimately replace Epogen and its $2 Billion in sales. Even though Amgen has a contract with Davita, there may be legal issues to continue to supply Epogen when there are safer products such as Triferic available. So some analys say hold your horses with the $2 billion and give RMTI credit for $200 million annual peak sales, the $2 billion could come sooner as safety is a concern. Patients will demand the safer product and Davita may have to break their contract early to avoid lawsuits. See a snippet of the article below:

    Amgen cutting 200 jobs despite improved Epogen sales
    Drugmaker had said in 2012 that it would halt Epogen production in Colorado
    January 31, 2014 | By Eric Palmer

    California-based biotech Amgen ($AMGN) reported a 30% leap in fourth-quarter profits this week, with improved sales of products like Prolia. It even reported higher sales of its anemia drug Epogen, which were up 10% for the quarter to more than half a billion dollars. But that is still not enough to save more than 200 jobs from the company's Epogen production operations in Colorado, which were targeted earlier as long-term sales of its anemia franchise have tapered off.

    On Thursday, the company told workers at Longmont and Boulder-area facilities that about 220 jobs would be cut by the end of April when the company suspends manufacturing there. Amgen spokeswoman Ashleigh Koss told FiercePharma today in an email that the company intends to hold on to some of the production capacity at the facility, "and may resume manufacturing in the future based on pipeline and inventory requirements."

    Read more: Amgen cutting 200 jobs despite improved Epogen sal

    Sentiment: Strong Buy

  • franchise_approval by franchise_approval Jan 30, 2014 12:19 PM Flag

    based on initial $25 is likely

144.31-2.50(-1.70%)Aug 27 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TubeMogul, Inc.
NasdaqGSWed, Aug 27, 2014 4:00 PM EDT
Burger King Worldwide, Inc.
NYSEWed, Aug 27, 2014 4:00 PM EDT